Maurizio Scaltriti
Maurizio Scaltriti
Подтвержден адрес электронной почты в домене
The epidermal growth factor receptor pathway: a model for targeted therapy
M Scaltriti, J Baselga
Clinical cancer research 12 (18), 5268-5272, 2006
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
S Chandarlapaty, A Sawai, M Scaltriti, V Rodrik-Outmezguine, ...
Cancer cell 19 (1), 58-71, 2011
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer
M Scaltriti, F Rojo, A Ocaña, J Anido, M Guzman, J Cortes, S Di Cosimo, ...
Journal of the National Cancer Institute 99 (8), 628-638, 2007
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
V Serra, B Markman, M Scaltriti, PJA Eichhorn, V Valero, M Guzman, ...
Cancer research 68 (19), 8022-8030, 2008
NTRK fusion-positive cancers and TRK inhibitor therapy
E Cocco, M Scaltriti, A Drilon
Nature reviews Clinical oncology 15 (12), 731-747, 2018
Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235
PJA Eichhorn, M Gili, M Scaltriti, V Serra, M Guzman, W Nijkamp, ...
Cancer research 68 (22), 9221-9230, 2008
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
V Serra, M Scaltriti, L Prudkin, PJA Eichhorn, YH Ibrahim, ...
Oncogene 30 (22), 2547-2557, 2011
PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition
YH Ibrahim, C García-García, V Serra, L He, K Torres-Lockhart, A Prat, ...
Cancer discovery 2 (11), 1036-1047, 2012
mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling
VS Rodrik-Outmezguine, S Chandarlapaty, NC Pagano, PI Poulikakos, ...
Cancer discovery 1 (3), 248-259, 2011
Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity
M Scaltriti, C Verma, M Guzman, J Jimenez, JL Parra, K Pedersen, ...
Oncogene 28 (6), 803-814, 2009
Convergent loss of PTEN leads to clinical resistance to a PI (3) Kα inhibitor
D Juric, P Castel, M Griffith, OL Griffith, HH Won, H Ellis, SH Ebbesen, ...
Nature 518 (7538), 240-244, 2015
HER kinase inhibition in patients with HER2-and HER3-mutant cancers
DM Hyman, SA Piha-Paul, H Won, J Rodon, C Saura, GI Shapiro, D Juric, ...
Nature 554 (7691), 189-194, 2018
The genomic landscape of endocrine-resistant advanced breast cancers
P Razavi, MT Chang, G Xu, C Bandlamudi, DS Ross, N Vasan, Y Cai, ...
Cancer cell 34 (3), 427-438. e6, 2018
Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients
M Scaltriti, PJ Eichhorn, J Cortés, L Prudkin, C Aura, J Jiménez, ...
Proceedings of the National Academy of Sciences 108 (9), 3761-3766, 2011
Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes
EA Mittendorf, Y Wu, M Scaltriti, F Meric-Bernstam, KK Hunt, S Dawood, ...
Clinical Cancer Research 15 (23), 7381-7388, 2009
Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal …
J Cortés, P Fumoleau, GV Bianchi, TM Petrella, K Gelmon, X Pivot, ...
J Clin Oncol 30 (14), 1594-1600, 2012
Biosynthesis of tumorigenic HER2 C‐terminal fragments by alternative initiation of translation
J Anido, M Scaltriti, JJ Bech Serra, BS Josefat, F Rojo Todo, J Baselga, ...
The EMBO journal 25 (13), 3234-3244, 2006
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer
A Bosch, Z Li, A Bergamaschi, H Ellis, E Toska, A Prat, JJ Tao, DE Spratt, ...
Science translational medicine 7 (283), 283ra51-283ra51, 2015
mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer
M Elkabets, S Vora, D Juric, N Morse, M Mino-Kenudson, T Muranen, ...
Science translational medicine 5 (196), 196ra99-196ra99, 2013
AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas
M Elkabets, E Pazarentzos, D Juric, Q Sheng, RA Pelossof, S Brook, ...
Cancer cell 27 (4), 533-546, 2015
В данный момент система не может выполнить эту операцию. Повторите попытку позднее.
Статьи 1–20